Beats Medical delivers evidence-based assessments and therapeutic interventions for neurological and neurodevelopmental conditions using high-quality software. Their Colbolt© platform facilitates objective digital assessments via mobile applications without extra hardware. While offering consumer-facing digital therapeutics for conditions like Parkinson's and Dyspraxia, the company primarily partners with pharmaceutical organizations to enhance clinical research and real-world evidence collection. By leveraging AI-driven insights, they aim to improve patient outcomes, accelerate drug development pipelines, and provide tailored digital therapies for behavioral change across complex CNS and rare disease populations.